Wednesday, April 19, 2023
Roche announced that the U.S. Food and Drug Administration (FDA) has approved Polivy® (polatuzumab vedotin-piiq) in combination with Rituxan® (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of adult patients with certain types of previously untreated diffuse large B-cell lymphoma.
The FDA approval of Polivy in combination with R-CHP brings a much-needed new treatment option which improves outcomes and bring other benefits to many patients with this aggressive lymphoma.
More than 70 countries have approved this Polivy combination for the treatment of adult patients with previously untreated DLBCL, including in the EU, UK, Japan, Canada and China.